Excited to present 🎤 first data #SABCS24 from TONIC2. Follow-up from https://t.co/07YbYYMKQ7. Are immune induction with dox or cisplatin indeed benefiting pts? @VeerleGeurts at P1-7-30 and new data on acquired resist🔬 to aPD1 at PS17-09 @NKI_nl @OncoAlert @NatureMedicine

Recent Nature paper on phase of menstrual cycle at start of breast cancer chemo suggests that this can affect chemo-sensitivity. More research needed on how this can result in cycle-driven-chemo-start. 💊💉Congrats ⁦@vanRheenen_Lab⁩ ⁦@NKI_nl⁩

This is well-deserved! Congrats @deVisserKarin 🥳🥳. She was one of the first scientists recognizing the importance of immune cells in breast tumors. Thanks to key leaders like Karin we now start doing trials specific for BC with high TILs #OPTImal study @NKI_nl @TILsWorkGroup

Fantastic PhD program at amazing institution @NKI_nl 👇

Mensen die naar ons land vluchten voor hun leven, voor de toorn van kwaadaardige regimes die we bestrijden bijvoorbeeld, wil de coalitie vanaf nu elke kans ontnemen nog iets van hun leven te maken…. Er is inderdaad een ernstige crisis gaande in ons land. Een morele crisis.

Stellar line up of speakers and spot on discussions and clinical cases! In the beautiful town of Padua🇮🇹 #AIBCC24 with @MOliveira_MD @vitti10 @prat_aleix @hoperugo and many others!

On my way to one of the best conferences on translational cancer research! #MAP24 🚆🚆💚💚

This will be amazing session #SABCS24 with stellar speakers and immune biomarkers inc TILs making their way to the clinic!

👀 We're looking for a junior group leader! Join our innovative, curiosity-driven institute in a collaborative, international environment. Full freedom to pursue your research, competitive salary & relocation support. 📅 Apply by Dec 1 Info & application: https://t.co/my1GSyAsQy

Thanks @ACIR_org for putting our work on neoadjuvant immunotherapy for TNBC in the spotlight @riannerolfes @Manon_deGraaf @LambrechtsDlab @NatureMedicine

Clinical Cancer Research is seeking a new Editor-in-Chief! Apply by September 30, 2024. Find out more: https://t.co/osxa1jTKgs

Had a fantastic meeting at the #ILCsymposium in beautiful Leuven, Belgium organized by @ChristineDesme2 and her team! Lots to think about, and lot more progress that needs to be made! @oesterreichs @Adrianvlee

Best break-out session ever on TME in lobular BC! Important especially since pts with ILC are often excluded from immunotherapy trials. Thanks for terrific organisation and location @ChristineDesme2 @elbcc #ilcsymposium @oesterreichs

A very impactful #ESMO24. Thanks @RebeccaDSing and great ESMO staff @myESMO @KKronig! Minor note: @NatureMedicine had even more concomitant papers of which 2 from @NKI_nl

#ceasefire now! ❤️‍🩹

Very excited that we see a 33% pCR rate with only 6 weeks of immunotherapy without chemo in TIL high TNBC. A lay version of our story👇. @NKI_nl @TILsWorkGroup @NatureMedicine

👇Wij zoeken een ervaren, enthousiaste, pro-actieve en flexibele Project Manager voor een groot, internationaal onderzoek om biomarker (TILs) naar de kliniek te brengen.

#ESMO24 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in TNBC with high TILs: BELLINI trial 🔍stage I-II, node negative, TILs ≥50%, 30 pts pCR Nivo+IPI➡️33% Nivo+RELA➡️47% 💥Remarkable efficacy of chemotherapy-free immunotherapy for immunogenic TNBC

Promising results with neoadjuvant nivo/relatlimab (LAG3 mAb) for mostly cT1c TNBC with high TILs: 47% pCR rate, 73% MPR. Immune toxicities remain an issue, with a case of diabetes mellitus. Terrific work from the team of @lab_kok — concomitant @NatureMedicine publication

A simultaneous publication of our BELLINI data @NKI_nl presented today as oral abstract on exploring nivo/ipi in TNBC without chemo. Thanks #ESMO24 and @NatureMedicine!